Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Rating) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 638,800 shares, a growth of 167.6% from the April 30th total of 238,700 shares. Based on an average daily volume of 217,100 shares, the days-to-cover ratio is currently 2.9 days. Currently, 6.2% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Thursday, May 18th. They set a “sell” rating for the company.

Tonix Pharmaceuticals Trading Down 2.9 %

TNXP traded down $0.05 during trading on Friday, hitting $1.65. 208,265 shares of the company’s stock traded hands, compared to its average volume of 440,348. The stock has a market capitalization of $17.06 million, a price-to-earnings ratio of -0.09 and a beta of 2.17. The company’s 50 day simple moving average is $3.19 and its two-hundred day simple moving average is $3.92. Tonix Pharmaceuticals has a 12-month low of $1.65 and a 12-month high of $29.94.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Rating) last announced its quarterly earnings results on Monday, March 13th. The company reported ($3.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($5.38) by $1.88. On average, equities analysts expect that Tonix Pharmaceuticals will post -9.56 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

A number of institutional investors have recently made changes to their positions in TNXP. Renaissance Technologies LLC lifted its position in Tonix Pharmaceuticals by 79.4% during the first quarter. Renaissance Technologies LLC now owns 19,200,435 shares of the company’s stock valued at $4,420,000 after purchasing an additional 8,500,604 shares in the last quarter. Tang Capital Management LLC purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at $1,754,000. BlackRock Inc. raised its stake in Tonix Pharmaceuticals by 12.3% during the first quarter. BlackRock Inc. now owns 34,392,362 shares of the company’s stock valued at $7,916,000 after purchasing an additional 3,760,804 shares in the last quarter. State Street Corp raised its position in Tonix Pharmaceuticals by 11.4% during the first quarter. State Street Corp now owns 7,446,104 shares of the company’s stock valued at $1,714,000 after purchasing an additional 764,518 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Tonix Pharmaceuticals by 7.8% in the first quarter. Northern Trust Corp now owns 4,139,924 shares of the company’s stock valued at $952,000 after acquiring an additional 300,199 shares during the period. Hedge funds and other institutional investors own 9.69% of the company’s stock.

Tonix Pharmaceuticals Company Profile

(Get Rating)

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800.